← Back to Search

EX/RP for Obsessive-Compulsive Disorder

University of Pennsylvania, Philadelphia, PA
Exposure & Response Prevention (EX/RP)N/ARecruitingLed by Edna B Foa, PhDResearch Sponsored by University of Pennsylvania

Study Summary

This trial will study whether delivering exposure and response prevention therapy to women during different phases in their menstrual cycle affects the success of the therapy and the women's OCD symptoms.

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with OCD according to the DSM-5 guidelines.
Select...
You must be able to take a break from your current treatment.
Select...
You have OCD that is moderate or severe in intensity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to approximately 4 weeks later
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to approximately 4 weeks later for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
OCD Symptoms
fMRI
Secondary outcome measures
rs fMRI

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Experimental 2Experimental Treatment1 Intervention
Half of female participants will be randomized to receive a brief EX/RP protocol in days 12-22 of the menstrual cycle (late follicular, early luteal phase).
Group II: Experimental 1Experimental Treatment1 Intervention
Half of female participants will be randomized to receive a brief EX/RP protocol within the first 10 days after the start of menstruation (early follicular phase).
Group III: Active ComparatorActive Control1 Intervention
Male participants will receive a brief EX/RP protocol within a 10-day window.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exposure & Response Prevention (EX/RP)
2014
N/A
~80

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,962 Previous Clinical Trials
42,527,721 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
National Institute of Mental Health (NIMH)NIH
2,717 Previous Clinical Trials
2,423,300 Total Patients Enrolled
66 Trials studying Obsessive-Compulsive Disorder
13,981 Patients Enrolled for Obsessive-Compulsive Disorder
New York State Psychiatric InstituteOTHER
469 Previous Clinical Trials
150,062 Total Patients Enrolled
25 Trials studying Obsessive-Compulsive Disorder
947 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Exposure & Response Prevention (EX/RP) Clinical Trial Eligibility Overview. Trial Name: NCT05359562 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Active Comparator, Experimental 1, Experimental 2
Obsessive-Compulsive Disorder Clinical Trial 2023: Exposure & Response Prevention (EX/RP) Highlights & Side Effects. Trial Name: NCT05359562 — N/A
Exposure & Response Prevention (EX/RP) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05359562 — N/A
Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT05359562 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being sought for this research study?

"Affirmative. Clinicaltrials.gov data attests to the active recruitment period of this study, which was initially published on June 15th 2022 and revised on July 7th 2022. This medical trial requires 120 participants from 2 sites for its completion."

Answered by AI

Who can partake in the experiment, and what criteria must they meet?

"This medical trial is recruiting 120 subjects, aged 18 to 45 years old and diagnosed with OCD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Women must be menstruating regularly, participants need not have taken psychotropic drugs in the past 12 weeks, exhibit moderate or greater severity symptoms at entry point and agree to a treatment free period. In addition willing participants must provide written informed consent after being briefed on study procedures."

Answered by AI

How many subjects are enrolled in this clinical experiment?

"Affirmative. The clinical trial is recruiting according to the data listed on clinicaltrials.gov, which was first posted on June 15th 2022 and has been modified most recently as of July 7th 2022. This medical study requires 120 volunteers between two sites."

Answered by AI

Does this clinical trial allow for participation from octogenarians?

"The eligibility criteria for this clinical trial specifies that participants must be between 18 and 45 years old. In addition, there are 3 studies intended to involve minors and a further 15 specifically targeted at seniors over 65."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
What site did they apply to?
University of Pennsylvania
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I seem to be having worsening issues with my ocd especially around my period when I'm feeling more emotional and I'd really like some help.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD
2022. "How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05359562.
All > Acth > Ocd
~77 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top